Sandoz Group AG (SDZNY)
| Market Cap | 30.39B |
| Revenue (ttm) | 10.59B |
| Net Income (ttm) | 227.00M |
| Shares Out | n/a |
| EPS (ttm) | 0.52 |
| PE Ratio | 133.88 |
| Forward PE | 19.42 |
| Dividend | 0.57 (0.81%) |
| Ex-Dividend Date | Apr 22, 2025 |
| Volume | 7,200 |
| Average Volume | 23,277 |
| Open | 70.49 |
| Previous Close | 69.97 |
| Day's Range | 70.15 - 71.14 |
| 52-Week Range | 35.61 - 71.14 |
| Beta | 0.27 |
| RSI | 68.34 |
| Earnings Date | Feb 25, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Sandoz Announces Launch Of TYRUKO In The US
(RTTNews) - Sandoz announced that TYRUKO or natalizumab-sztn is available to patients in the US. Developed by Polpharma Biologics, TYRUKO is the only FDA approved natalizumab biosimilar for the treatm...
James M. O'Brien Appointed Chief Financial Officer at Mesoblast
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection wi...
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wed...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
Sandoz To Acquire Just-Evotec Biologics EU SAS In Strategic Biosimilars Expansion Deal
(RTTNews) - Sandoz (SDZNY) announced a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS), including its Toulouse-based...
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec (EVO) Sells Biologics Site to Sandoz for $350M
Evotec signs deal with Sandoz for Just - Evotec Biologics site
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Drugmakers must face skincare drug price-fixing lawsuit, US judge rules
A federal judge on Friday said 36 drugmakers and executives must face nearly all claims in an antitrust lawsuit brought by most U.S. states, accusing them of conspiring to fix prices of 80 generic dru...
SDZNY vs. STVN: Which Stock Is the Better Value Option?
SDZNY vs. STVN: Which Stock Is the Better Value Option?
Sandoz Group AG (SDZNY) Q3 2025 Sales Call Transcript
Sandoz Group AG (OTCQX:SDZNY) Q3 2025 Sales Call October 30, 2025 4:00 AM EDT Company Participants Craig Marks - Head of Investor Relations Richard Saynor - Chief Executive Officer Remco Steenbergen -...
Sandoz Group AG (SDZNY) Q3 2025 Sales/ Trading Statement Call - Slideshow
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta
Sandoz granted tentative approval for generic of Pfizer's Inlyta
Sandoz gets FDA tentative approval for a generic of Pfizer’s kidney cancer drug Inlyta, but launch is delayed by patent litigation. Read more here.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
PRINCETON, N.J.--(BUSINESS WIRE)--Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent appro...
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar
Sandoz welcomes Quebec government support for Boucherville plant modernization project
Sandoz underlines importance of Delpharm Boucherville plant modernization project, made possible by total investment of CAD 220 million Amount includes joint investments from provincial and federal go...
Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets
Lupin Limited announced on August 12 that it has entered into a licensing and commercialization agreement with Switzerland-based Sandoz Group AG for its biosimilar Ranibizumab. The deal covers multipl...
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support gl...
Sandoz Group AG 2025 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Sandoz Group AG in conjunction with their 2025 Q2 earnings call.
Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, t...
Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports
Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard ...